Du er her: Forside > In the pit - Oslo Børs > Targovax- et spennende farma-selskap
Targovax- et spennende farma-selskap
VetIkke123
11:07 12.06.2017
#60

Tok et lodd Trvx i dag på 21.8. Forvente en rekkyl opp mot 27-32 snart.
yemaya 2
22:02 12.06.2017
#8444

Copypast fra gamletråden:

Det kommer en reparasjonsemisjon på NOK 40m som vil være åpen for tegning 3-14. juli. Tegningsretter vii henhold til eierliste per 8. juni 2017. God aften fra Harry.

Stockamateur
10:02 14.06.2017
#12040

Tok noe TRVX jeg også. Ser ut til å være grei støtte ved 20. Emisjonsspøkelset som diskutert i forrige TRVX topic har også manifestert seg.

Stopp rett under 20.

Endret 14.06.2017 10:02 av Stockamateur
Stockamateur
10:45 16.06.2017
#12061

Hvor grådig skal man være i TRVX? Target 28-29?
Stockamateur
10:04 28.06.2017
#12093

Stoppet ut i dag tidlig.
Stockamateur
10:35 29.09.2017
#12173

Ikke noe moro med TRVX etter siste innlegg. Siger nedover.
highlander
14:01 11.12.2017
#7737

TRVX med børsmelding i dag:

"Oslo, Norway, 11 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the treatment of melanoma and mesothelioma have successfully passed their respective first, planned, independent safety reviews. These are the first studies to investigate ONCOS-102 in combination with other drugs.

The safety reviews of ONCOS-102 in the first four patients in the melanoma trial and first three patients in the mesothelioma trial have been completed without any safety concerns. The review reports conclude that, to date, ONCOS-102 has been well-tolerated in combination with either checkpoint inhibitor (KEYTRUDA®), or chemotherapy (pemetrexed/cisplatin), and both trials were recommended to be continued by the study-specific safety committees.

The melanoma trial is an open-label phase I trial exploring the safety, immune activation and clinical response of sequential treatment with ONCOS-102 and the checkpoint inhibitor KEYTRUDA® (pembrolizumab, an anti-PD-1 monoclonal antibody) in patients with advanced or unresectable melanoma, whose tumors have continued to grow despite checkpoint inhibitor therapy. The goal of the trial is to investigate whether the immune system of patients, who have already failed to respond to checkpoint inhibitors, can be reactivated by priming with ONCOS-102 and whether this reactivation enables them to respond to subsequent retreatment with a checkpoint inhibitor.

The mesothelioma trial is a randomized phase II, open-label, multi-center trial with a phase Ib safety lead-in of ONCOS-102 and standard of care pemetrexed/cisplatin (chemotherapy) in patients with unresectable malignant pleural mesothelioma. The trial will include six patients in a lead-in to evaluate safety, followed by a randomized part of the trial to compare the combination treatment with the standard of care chemotherapy.

Dr Magnus Jäderberg, CMO of Targovax, said: "We are pleased that the first combination trials of ONCOS-102 have passed the initial safety reviews without any issues. As such, ONCOS-102 appears to be well-tolerated in combination with both checkpoint inhibition and chemotherapy, and we can proceed with the trials as planned. Our plan now is to evaluate immune responses in the first subset of patients".

Immune response data readout schedule

Over the coming weeks and months, Targovax expects to release immune response data in a subset of patients for these two trials, in addition to the TG02 RAS neo-antigen vaccine trial in colorectal cancer, according to the following schedule:

In December: TG02 in colorectal cancer
In January: ONCOS-102 in melanoma
In February: ONCOS-102 in mesothelioma"
driller
19:40 11.12.2017
#10528

Et steg i riktig retning også for TRVX nå. Potensialet er stort, og de neste to månedene blir spennende.
driller
10:18 09.01.2018
#10530

Ser ut som om flere begynner å få opp øynene for TRVX etterhvert. Selskapet holder stø kurs mot himmelen med flere gode meldinger i det siste, selv om kursen har vært bedrøvelig en stund.
driller
07:25 07.02.2018
#10538

Oslo, Norway, 7 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces completion of the safety lead-in cohort and preliminary immune activation data in the phase I/II trial of ONCOS-102 in mesothelioma in combination with standard of care chemotherapy.

The trial is a randomized phase I/II open label trial, with a six-patient safety lead-in cohort, of ONCOS-102 and pemetrexed/cisplatin, the current standard of care chemotherapy, in 1st and 2nd line patients with unresectable malignant pleural mesothelioma. The trial aims to assess safety, tumor targeted immune activation and clinical benefit of the combination of ONCOS-102 and chemotherapy compared to chemotherapy alone.

The independent Data and Safety Monitoring Board (DSMB) have now reviewed all six patients in the safety lead-in cohort of the trial. No concerns were raised, and the DSMB have recommended that the randomized part of the trial can be initiated, with recruitment of another 24 patients.

In addition, early immune activation has been assessed for a subset of the patients. Systemic release of several pro-inflammatory cytokines was observed (3/3 patients analyzed), demonstrating that the treatment triggers an innate immune response. Also, there was an increase in the relative level of tumor infiltrating cytotoxic CD8+ T-cells (2/2 patients with pre- and post-treatment biopsies analyzed), indicating an activation of the adaptive immune system in the lesions. These data are important, as they show that the treatment of ONCOS-102 in combination with chemotherapy induces both innate and adaptive immune activation in patients, as well as triggering changes in the tumor microenvironment, which indicate that the tumors may become susceptible to an attack by the immune system.

Magnus Jäderberg, CMO of Targovax, said: "We are very pleased that the safety lead-in cohort was completed without any concerns, and that we now can move into the randomized part of the trial. The systemic and lesional immune activation are in line with what we saw in the mesothelioma patients from our phase I trial, in which there was an associated clinical response. It will therefore be interesting to follow what clinical benefits may be seen in the subsequent randomized part of the ongoing trial."
driller
12:40 21.02.2018
#10540

Merch kjøper det australske immunterapi-selskapet Viralytics. Oppkjøpsbølgen i bransjen er voldsom og det slutter nok ikke der. Bare i januar ble det gjort oppkjøp og fusjoner tilsvarende 27,5 milliarder USD i biotech-bransjen. NANO og Targovax er begge hete kandidater for de store internasjonale selskapene.
driller
20:04 18.04.2018
#10548

Spennende tider med mange oppkjøp i bransjen, og snart tid for readouts i TRVX. Flere her som følger denne?
oge
20:47 18.04.2018
#18216

Jeg har en liten post, men er i solid minus. Har tre pharma, men ikke Bergenbio. Går en, veier gevinsten tapet opp i de alle med god margin. Dette er lotto for meg. Jeg skjønner ikke bæra av hva de sier. Og burde kanskje skjønt. Men jeg vet vi trenger medisiner som funnker. Derav innsatsen. Noen vinner jo, men dauer alle tilslutt.
driller
20:56 18.04.2018
#10549

Grei oppsummering det oge :-) Jeg har noe i TRVX og litt i NANO, har mest tro på førstnevnte.

Endret 18.04.2018 20:56 av driller
highlander
08:53 02.05.2018
#9650

Targovax melder i dag at de har sett lovende resultater fra sin fase I/II test av ONCOS-102 i mesothelioma, i kombinasjon med standard kjemoterapi. De opplyser at det ble observert klinisk respons hos tre av de seks første pasientene:

Oslo, Norway, 2 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces encouraging results from its phase I/II trial of ONCOS-102 in mesothelioma, in combination with standard of care chemotherapy, in which clinical responses were observed in three out of the first six patients.

The trial is a randomized phase I/II open label trial, with a six-patient safety lead-in cohort, of ONCOS-102 and pemetrexed/cisplatin, the current standard of care chemotherapy, in patients with unresectable malignant pleural mesothelioma.

The aim of the trial is to assess safety and tolerability, immunological activation and overall response rate of the combination of ONCOS-102 and chemotherapy compared to chemotherapy alone. In February, Targovax reported that the independent Data and Safety Monitoring Board (DSMB) had assessed the safety data from the lead-in cohort, and recommended the trial continue into the randomized phase without modifications. In addition, innate and adaptive immune activation was observed in the first patients analyzed.

Now, overall response rate has been evaluated for all six patients in the safety cohort after six months. Three out of the six patients (50%) responded, with one patient showing a partial response and two patients showing stable disease, according to the Response Evaluation Criteria In Solid Tumors guidelines, RECIST 1.1.

All patients in the safety cohort received ONCOS-102 and chemotherapy combination treatment either as 1st line (three patients), or after previous treatment (three patients, 2nd/3rd line). Two out of three patients in 1st line responded, and one of three patients that had received previous treatment responded.

Based on this early signal of efficacy, and the previous DSMB recommendation, recruitment into the randomized part of the trial is now underway. The trial will include 30 patients when fully recruited, with 20 patients in the experimental group (including the safety cohort) and 10 patients in the control group.

Dr. Luis Paz-Ares, Chair of the Medical Oncology Department at the University Hospital 12 de Octubre, Madrid and Principal Investigator of the trial said: "Mesothelioma is a challenging disease to treat, with few patients surviving beyond 12 months from diagnosis. The three clinical responses observed in the safety lead-in cohort of the ONCOS-102 trial are encouraging. We look forward to entering the randomized part of the trial which will further evaluate the potential of this novel, innovative treatment to benefit more patients in the future."

Magnus Jäderberg, CMO of Targovax, added: " We are very pleased to have completed the safety part of the study, with the DSMB giving us approval to open up the randomized part and start recruiting patients. This is the first time clinical response has been observed for ONCOS-102 in combination with chemotherapy, which is an important milestone for Targovax and the ONCOS program. It will now be interesting to see if this early signal of efficacy is confirmed in the randomized part of the study."
highlander
13:47 24.05.2018
#10193

[Beklager! Nye innlegg er bare tilgjengelig for abonnenter! Allerede registrert? Logg inn eller Gå til registrering og kjøp abonnement!]
driller
07:06 25.05.2018
#10555

[Beklager! Nye innlegg er bare tilgjengelig for abonnenter! Allerede registrert? Logg inn eller Gå til registrering og kjøp abonnement!]
driller
14:22 26.05.2018
#10556

[Beklager! Nye innlegg er bare tilgjengelig for abonnenter! Allerede registrert? Logg inn eller Gå til registrering og kjøp abonnement!]
highlander
21:47 11.06.2018
#10451

[Beklager! Nye innlegg er bare tilgjengelig for abonnenter! Allerede registrert? Logg inn eller Gå til registrering og kjøp abonnement!]
driller
22:04 11.06.2018
#10557

[Beklager! Nye innlegg er bare tilgjengelig for abonnenter! Allerede registrert? Logg inn eller Gå til registrering og kjøp abonnement!]
OldNick
12:44 12.06.2018
#20249

[Beklager! Nye innlegg er bare tilgjengelig for abonnenter! Allerede registrert? Logg inn eller Gå til registrering og kjøp abonnement!]
highlander
15:31 13.06.2018
#10475

[Beklager! Nye innlegg er bare tilgjengelig for abonnenter! Allerede registrert? Logg inn eller Gå til registrering og kjøp abonnement!]
highlander
13:05 19.06.2018
#10576

[Beklager! Nye innlegg er bare tilgjengelig for abonnenter! Allerede registrert? Logg inn eller Gå til registrering og kjøp abonnement!]
highlander
12:47 12.07.2018
#11025

[Beklager! Nye innlegg er bare tilgjengelig for abonnenter! Allerede registrert? Logg inn eller Gå til registrering og kjøp abonnement!]
driller
11:01 15.07.2018
#10558

[Beklager! Nye innlegg er bare tilgjengelig for abonnenter! Allerede registrert? Logg inn eller Gå til registrering og kjøp abonnement!]
Varsling på tema     Varsling på stikkord




StockTalk er en tjeneste levert av Kreateam Consult AS. Orgnr. 911 839 806 MVA
Adresse: Postboks 39 Holmlia, 1201 Oslo. Email: st@stocktalk.no Tlf. 40 07 31 70
Kontakt oss | Hjelp | Regler | Sett som startside | Legg til favoritter